來自中山大學(xué)腫瘤防治中心腫瘤國(guó)家重點(diǎn)實(shí)驗(yàn)室的研究人員發(fā)現(xiàn)了鼻咽癌血清診斷的一種新標(biāo)記,，這對(duì)于鼻咽癌的診斷和治療具有積極意義,。這一研究成果公布在Journal of General Virology雜志上,。
長(zhǎng)期以來,，Epstein–Barr 病毒（簡(jiǎn)稱EB病毒）一直被認(rèn)為是人類某些嚴(yán)重疾病以及腫瘤的致病因子,，它與許多疾病的發(fā)生都有著密切的關(guān)系,，威脅著人類的健康,，因而一直倍受關(guān)注。
之前的研究顯示,，IgA 和（或）IgG對(duì)幾種不同的EB病毒的不同反應(yīng)有利于鼻咽癌NPC的診斷,，但是不同抗體對(duì)gp78的作用至今并未進(jìn)行相關(guān)研究。
在這篇文章中,，研究人員利用Luminex的multi-analyte profiling (xMAP)技術(shù),，分析抗體對(duì)gp78合成多肽的反應(yīng)（樣品包括95位鼻咽癌病患樣品和91個(gè)陰性對(duì)照），結(jié)果研究人員發(fā)現(xiàn)NPC針對(duì)的IgA-gp78特異性是71％,，而IgG-gp78則是73％,。
之后研究人員還通過一系列組合方式進(jìn)行研究，最后確定針對(duì)EB病毒的gp78的抗體是一種對(duì)于鼻咽癌xMAP技術(shù)檢測(cè)血清診斷的新標(biāo)記,，這對(duì)于鼻咽癌的診斷和治療具有積極意義。（生物谷Bioon.com）
生物谷推薦原始出處：
J Gen Virol 89 (2008), 1152-1158; DOI 10.1099/vir.0.83686-0
Antibodies against Epstein–Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology
Ai-Di Gu1, Yan-Bo Xie1, Hao-Yuan Mo1,2, Wei-Hua Jia1, Miao-Yan Li3, Ming Li3, Li-Zhen Chen1, Qi-Sheng Feng1, Quentin Liu1, Chao-Nan Qian1,2 and Yi-Xin Zeng1
1 State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Center, Sun Yat-Sen University, Guangzhou, PR China
2 State Key Laboratory of Oncology in Southern China; Department Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-Sen University, Guangzhou, PR China
3 Da'an Gene Diagnostic Center, Sun Yat-Sen University, Guangzhou, PR China
Immunoglobulin (Ig) A and/or IgG reactivities to several Epstein–Barr virus (EBV) antigens have been used to facilitate diagnosis of nasopharyngeal carcinoma (NPC). However, antibodies against gp78, an EBV membrane glycoprotein, have not been examined to this day. In this study, we utilized Luminex multi-analyte profiling (xMAP) technology to analyse antibody responses to a synthetic peptide of gp78 in sera samples from 95 NPC patients and 91 healthy controls. Our results showed the sensitivity and specificity of IgA-gp78 for NPC diagnosis were 79 and 71 %, respectively, while those of IgG-gp78 were 74 and 73 %, respectively. The IgA and IgG responses to different EBV antigens were not identical within an individual and IgA-gp78 and IgG-gp78 could be complementary to antibodies against viral capsid antigen (VCA), the diffused early antigen (EA-D) and the nuclear antigen EBNA1 for NPC diagnosis. When the six EBV parameters for NPC prediction, i.e. IgA-gp78, IgG-gp78, IgA-VCA, IgA-EBNA1, IgA-EA-D and IgG-EA-D, are combined, the combined predictors were able to reach overall sensitivity and specificity of 91 and 95 %, respectively. Thus, simultaneous detection of these EBV serological markers could improve the predictive values of NPC using xMAP technology.
